Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Hepatitis C Virus RNA-Targeted Therapeutics

    SBC: VIOGEN BIOSCIENCES, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection is a significant human health issue, accounting for 50% of liver transplants in the US, with approximately 170 million persons infected worldwide. The current standard of care therapy of PEGylated-interferon and ribavirin is effective in only about 50% of patients, with severe side effects and contraindications limiting patient ...

    STTR Phase I 2014 Department of Health and Human Services
  2. Selective activation of the vagus nerve as an improved therapy for heart failure

    SBC: BLACKROCK MICROSYSTEMS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The goal of the proposed project is to alleviate the enormous public health burden of heart failure. Heart failure leads to significant morbidity and mortality, affects almost five million Americans, and results in morethan 35 billion dollars in annual healthcare costs. Current pharmacological and surgical treatments are only moderately effective and can have s ...

    STTR Phase I 2014 Department of Health and Human Services
  3. Rapid Monitoring and Assessment of Tubercuolosis Treatment at the Point of Care Using Breath

    SBC: NanoSynth Materials and Sensors Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Problem and Significance According to the CDC global statistics nearly of the world is infected with Tuberculosis TB In million f peopled infected lived in what is considered a high burden country Countries such as India Peru China sub Saharan Africa and others have significant regions endemic for TB particularly among the lower income ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

    SBC: TheraTarget, Inc.            Topic: NCI

    DESCRIPTION provided by applicant The purpose of this Phase II STTR project is to develop a polymeric system for the combination delivery of two antineoplastic agents gemcitabine and paclitaxel Based on the successful results of the STTR Phase I award this Phase II proposal details the rationale and research plan for the synthesis and evaluation of in vivo efficacy of two novel macromolecula ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms

    SBC: TheraTarget, Inc.            Topic: 106

    NARRATIVE This STTR Phase I proposal details the rationale and the research plan for the development of a novel liquid embolizing agent composed of the genetically engineered protein polymerSELPsilk elastinlike proteinKto embolize cerebral aneurysmsThe SELP embolic would reduce the risk of aneurysm rupture while minimizing the risk of recanalization after treatment and providing a platform for del ...

    STTR Phase I 2017 Department of Health and Human Services
  9. Visually driven disease variant analysis empowering real time clinical research

    SBC: Frameshift Labs, Inc.            Topic: NHGRI

    Project Summary Identifying disease causing genetic variants is a complex process that requires experts from multiple fields including bioinformatics IT systems administration and disease pathology to work closely together The size of sequencing data files also adds the requirement for large computational resources As a result performing genomic analyses is an ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government